In terms of neoadjuvant therapy, 25% of the metastatic patients received this treatment compared to 13.7% in the non-metastatic group, although this difference did not reach statistical significance (p=0.061).
← all excerpts
Risk factors for pelvic lymph node metastasis in cervical cancer: a retrospective analysis of 186 patients.
1
0.0610
0.0610